Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.

Qi-Feng ChenXiong-Ying JiangYue HuSong ChenJun-Zhe YiSui-Xing ZhongJiong-Liang WangNing LyuMing Zhao

Published in: Journal of hepatocellular carcinoma (2024)

In this cost-effectiveness evaluation, SoHAIC demonstrated cost-effectiveness over sorafenib for HCC with major portal vein tumor thrombosis, as observed from the perspective of a Chinese payer.

Keyphrases

pulmonary embolism
low dose
locally advanced
radiation therapy
chemotherapy induced